Publications (17) Alfonso Jesús Domínguez-Gil Hurlé publications

filter_list Allergy and Immunology

2016

  1. A pharmacist's role in the individualization of treatment of HIV patients

    Personalized Medicine, Vol. 13, Núm. 2, pp. 169-188

  2. Gene–gene interactions between DRD3, MRP4 and CYP2B6 polymorphisms and its influence on the pharmacokinetic parameters of efavirenz in HIV infected patients

    Drug Metabolism and Pharmacokinetics, Vol. 31, Núm. 5, pp. 349-355

  3. Influence of the number of daily pills and doses on adherence to antiretroviral treatment: A 7-year study

    Journal of Clinical Pharmacy and Therapeutics, Vol. 41, Núm. 1, pp. 34-39

2015

  1. CYP3A4 polymorphism and lopinavir toxicity in an HIV-infected pregnant woman

    Clinical drug investigation, Vol. 35, Núm. 1, pp. 61-66

2014

  1. Population pharmacokinetic/pharmacogenetic model of lopinavir/ritonavir in HIV-infected patients

    Personalized Medicine, Vol. 11, Núm. 7, pp. 693-704

2013

  1. Impact of a pharmaceutical care program on clinical evolution and antiretroviral treatment adherence: A 5-year study

    Patient Preference and Adherence, Vol. 7, pp. 729-739

2011

  1. Population pharmacokinetic/pharmacogenetic model for optimization of Efavirenz therapy in caucasian HIV-infected patients

    Antimicrobial Agents and Chemotherapy, Vol. 55, Núm. 11, pp. 5314-5324

  2. Population pharmacokinetics of lopinavir/ritonavir (kaletra) in HIV-infected patients

    Therapeutic Drug Monitoring, Vol. 33, Núm. 5, pp. 573-582

1995

  1. Binding of roxithromycin to total plasma proteins, albumin, polymorphonuclear cells and lymphocytes

    Revista Espanola de Quimioterapia, Vol. 8, Núm. 1, pp. 46-50

  2. Uptake of antibiotics by phagocytic cells: Study methods and therapeutic implications

    Revista Espanola de Quimioterapia, Vol. 8, Núm. 2, pp. 100-108

1991

  1. Effect of dose on the kinetic behaviour of valproic acid: modifications in plasma protein binding.

    European journal of drug metabolism and pharmacokinetics, Vol. Spec No 3, pp. 239-242

1987

  1. Efficacy of maintenance of therapeutic serum concentrations of theophylline in chronic asthma

    International Journal of Clinical Pharmacology Therapy and Toxicology, Vol. 25, Núm. 3, pp. 157-162

1986

  1. Individualization of theophylline dosage in adults with bronchial asthma

    Drug Intelligence and Clinical Pharmacy, Vol. 20, Núm. 9, pp. 704-707

  2. Pleural fluid levels of cefoxitin in patients with renal impairment

    International Journal of Clinical Pharmacology Therapy and Toxicology, Vol. 24, Núm. 9, pp. 485-489

1984

  1. Influence of dose in the urinary excretion of amikacin

    International Journal of Clinical Pharmacology Therapy and Toxicology, Vol. 22, Núm. 10, pp. 538-542

  2. Pharmacokinetics of cefoxitin administered by i.v. infusion to patients with a pleural effusion

    European Journal of Clinical Pharmacology, Vol. 26, Núm. 3, pp. 389-392

1981

  1. Disposition of cefoxitin in patients with pleural effusion

    Clinical Therapeutics, Vol. 3, Núm. 6, pp. 425-435